Apollomics
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
989 E Hillsdale Blvd Ste 220, Foster Cit...Phone Number
(650) 209-4055Website
www.apollomicsinc.comRevenue
-Stock Symbol
APLMIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Apollomics
Apollomics is a biotechnology company focused on discovering and developing oncology therapies designed for combination treatment approaches. The company advances cancer drug candidates that target specific molecular pathways and immune related mechanisms to improve outcomes for patients with difficult to treat cancers.Explore more
Apollomics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Apollomics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Apollomics
Apollomics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Apollomics launches new products
Funding: Get notified immidiatlly once Apollomics has new funding data
Website visits: Recent activity has been detected on your website
Check if Apollomics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Apollomics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Apollomics is spiking on competitors!
Click to see if Apollomics had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Apollomics
Compare insights from companies similar to Apollomics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Apollomics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Apollomics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Apollomics.
Apollomics financials insights
Gather financial insights about Apollomics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Angel/Seed
$5M
Series A
$9.8M
2019
Series B
$100M
2020
Series C
$124.2M
2026
Debt
$2M
Apollomics Tech Stack
A closer look at the technologies used by Apollomics
Most Recent Scoops
Funding
Funding
Pain Point
Project
, according to a high-level source in accounting, is planning to remediate challenges related to document scanning and signing. The organization is currently evaluating various vendors. The organization plans to leverage DocuSign tools.
Pain Point, Accounting, Document Management, Financial Reporting, Finance
Project
, according to a high-level source in accounting, has completed initiatives related to tax compliance within the last twelve months.
Accounting, Compliance, Financial Reporting, Finance, Tax
Project
, according to a high-level source in accounting, has completed initiatives related to payroll within the last twelve months.
Accounting, Compensation & Benefits, Financial Reporting, Finance
Project
Accounting, Financial Reporting, Finance
Apollomics News & Media
Apollomics Inc. Announces $2.0 Million Bridge Financing
Apollomics Inc. Announces $2.0 Million Bridge FinancingApollomics Reports First Half 2025 Financial Results
FOSTER CITY, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced financial results for the first half of 2025 ended June 30, 2025.Apollomics Announces Settlement of Cayman Litigation
FOSTER CITY, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”) (Nasdaq: APLM) announced today entering into a settlement agreement (the “Settlement Agreement” or the “Agreement”) with TWVC Goldlink Partners Investment Limited and TWVC Panglin Group Investment Limited (together, “TWVC”), entities represented by Triwise Capital Management Ltd, in connection with the litigation previously filed in the Grand Court of the Cayman Islands (the “Cayman Litigation”Apollomics Announces Changes to its Board of Directors and Composition of Committees
FOSTER CITY, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California-based late-stage clinical biopharmaceutical company, today announced the following update regarding changes to the Company’s board of directors (“Board”) and composition of committees.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Apollomics
Sign Up For FreeTo access detailed company insights
Apollomics is a biotechnology company focused on discovering and developing oncology therapies designed for combination treatment approaches. The company advances cancer drug candidates that target specific molecular pathways and immune related mechanisms to improve outcomes for patients with difficult to treat cancers.... Read More
